Major Findings
In this study of 1,000 randomly selected Abbott Confirm Rx devices monitored on Merlin.net, 644 devices transmitted 95,716 arrhythmia EGMs (i.e., AF, tachycardia, bradycardia, or pause) over a median follow-up duration of 8.1 months. EGMs were transmitted at a median rate of 4.1 EGMs/pt/mo across the entire population. However, the top 25% of patients transmitted a median of 24.4 total EGMs/pt/mo, and accounted for roughly 90% of all EGMs. Key EGM selection reduced the EGM review burden by 55.1%, with no delay-to-diagnosis in 99.2% of patients exhibiting true arrhythmias.